Novel Allogenic CD19-targeting CAR-T Cell Therapy (QH103E) in r/r NHL
Status:
RECRUITING
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
CD19-CAR-T cell therapy is a cellular immunotherapy targeting CD19 to perform CAR modification on allogeneic T cells. A novel version of the CAR-T product by gene editing (QH103E) that has been validated for resistance to alloreactive T cell killing and enhancement of memory efficacy will be used in this study.
This is a single center, prospective, open-label, single-arm, phase 1/2 study. A total of around 30 patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) will be enrolled in the study and receive QH103E product infusion. Phase 1 (n=9 to 12) is dose escalation part, and phase 2 (n=15 to 20) is expansion cohort part. The primary objective of this study was to evaluate the safety and efficacy of QH103E in patients with r/r B-cell NHL.